Log in
(Ad)
What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%? Wall Street legend Paul Mampilly recently identified this as the stock of the century. Buying up a handful of shares of this small company now could change your life and even make you millions.

NASDAQ:ALPN - Alpine Immune Sciences Stock Price, Forecast & News

$3.10
-0.53 (-14.60 %)
(As of 01/23/2020 05:32 AM ET)
Add
Compare
Today's Range
$3.10
Now: $3.10▼
$3.63
50-Day Range
$2.95
MA: $3.64▼
$4.40
52-Week Range
$2.25
Now: $3.10▼
$8.24
Volume38,400 shs
Average Volume12,604 shs
Market Capitalization$57.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
Previous Symbol
CUSIPN/A
CIK1626199
Webhttp://www.alpineimmunesciences.com/
Phone206-788-4545

Debt

Debt-to-Equity Ratio0.47
Current Ratio3.84
Quick Ratio3.84

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$700,000.00
Price / Sales82.33
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.22 per share
Price / Book0.96

Profitability

EPS (Most Recent Fiscal Year)($2.63)
Net Income$-36,490,000.00
Net MarginsN/A
Return on Equity-103.29%
Return on Assets-72.97%

Miscellaneous

Employees48
Outstanding Shares18,590,000
Market Cap$57.63 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:ALPN Rates by TradingView

(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) released its quarterly earnings data on Wednesday, November, 13th. The biotechnology company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. The biotechnology company earned $0.29 million during the quarter, compared to analyst estimates of $0.38 million. View Alpine Immune Sciences' Earnings History.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Alpine Immune Sciences.

What price target have analysts set for ALPN?

2 brokerages have issued 12 month price targets for Alpine Immune Sciences' shares. Their forecasts range from $8.00 to $13.00. On average, they expect Alpine Immune Sciences' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 238.7% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.

What is the consensus analysts' recommendation for Alpine Immune Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.

Has Alpine Immune Sciences been receiving favorable news coverage?

Media coverage about ALPN stock has trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Alpine Immune Sciences.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest in December. As of December 13th, there was short interest totalling 19,000 shares, an increase of 49.6% from the November 28th total of 12,700 shares. Based on an average daily volume of 23,400 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.2% of the shares of the stock are short sold. View Alpine Immune Sciences' Current Options Chain.

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the folowing people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 48)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $3.10.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $57.63 million and generates $700,000.00 in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe.View Additional Information About Alpine Immune Sciences.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is http://www.alpineimmunesciences.com/.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  656
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel